Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application

Simona Ceccarelli¹, Paola Pontecorvi¹, Eleni Anastasiadou¹, Claudio Napoli²,₃ and Cinzia Marchese¹*

¹ Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy, ² Clinical Department of Internal Medicine and Specialistics, Department of Advanced Clinical and Surgical Sciences, Università della Campania “Luigi Vanvitelli”, Naples, Italy, ³ IRCCS SDN, Naples, Italy

Adipose-derived stem cells (ASCs) represent a promising tool for soft tissue engineering as well as for clinical treatment of inflammatory and autoimmune pathologies. The well-characterized multi-differentiation potential and self-renewal properties of ASCs are coupled with their immunomodulatory ability in providing therapeutic efficacy. Yet, their impact in immune or inflammatory disorders might rely both on cell contact-dependent mechanisms and paracrine effects, resulting in the release of various soluble factors that regulate immune cells functions. Despite the widespread use of ASCs in clinical trials addressing several pathologies, the pathophysiological mechanisms at the basis of their clinical use have been not yet fully investigated. In particular, a thorough analysis of ASC immunomodulatory potential is mandatory. Here we explore such molecular mechanisms involved in ASC immunomodulatory properties, emphasizing the relevance of the milieu composition. We review the potential clinical use of ASC secretome as a mediator for immunomodulation, with a focus on in vitro and in vivo environmental conditions affecting clinical outcome. We describe some potential strategies for optimization of ASCs immunomodulatory capacity in clinical settings, which act either on adult stem cells gene expression and local microenvironment. Finally, we discuss the limitations of both allogeneic and autologous ASC use, highlighting the issues to be fixed in order to significantly improve the efficacy of ASC-based cell therapy.

Keywords: adipose-derived stem cells, immunomodulation, microenvironment, cytokines, clinical application

INTRODUCTION

Adipose-derived mesenchymal stem cells (ASCs) represent a population of self-renewing multipotent adult cells in the vascular stroma of adipose tissues, playing important roles in development, post-natal growth, maintenance of tissue homeostasis and tissue repair and regeneration (Shingyochi et al., 2015; Dai et al., 2016). Significant amount of ASCs can be readily accessible from subcutaneous liposuction and, when appropriately stimulated, they can further differentiate into several cell-like types, including adipocytes, osteocytes, neural cells, vascular endothelial cells, cardiomyocytes, pancreatic cells, and hepatocytes (Zuk et al., 2001, 2002; Planat-Bénard et al., 2004; Aurich et al., 2009; Dave et al., 2014; Sommese et al., 2017). To date, mechanisms responsible for ASC therapeutic efficacy have been only partially investigated. The common belief is that their action relies on three major events: (1) multi-differentiation potential, (2) self-renewal
properties and (3) immunomodulatory capacity. In particular, the first could account for their impact on tissue engineering applications, due to the ability to differentiate into tissue-specific cells and into endothelial cells, thus stimulating both tissue regeneration and arteriogenesis. Indeed, several researchers have analyzed the efficacy of ASC-based therapy in restoring cardiac function in ischemic heart diseases (IHD) (Valina et al., 2007; Naaijkens et al., 2014), providing evidence of an extremely low rate of survival and cardiac retention of ASCs after transplantation. Such indications suggest that ASC therapeutic efficacy in IHD should be ascribed mainly to their paracrine effects rather than the direct differentiation into cardiovascular lineage cells (Yang et al., 2013). So, evaluation of ASC therapeutic potential should take into account both cell retention and survival after transplantation and production of active paracrine factors (Li et al., 2019).

The proliferative potential could represent a key element to consolidate the results obtained by ASC injection, leading to the generation of a relatively stable clone of self-renewing cells within the target tissue. Regarding the immunomodulatory capacity, it has been demonstrated that ASCs, as well as BMSCs, have a hypoimmunogenic phenotype, since they lack the major MHC class II molecules and express only low levels of MHC class I, this allowing them to evade immune recognition (Puissant et al., 2005; McIntosh et al., 2006). Furthermore, ASCs can act as modulators of the host response, showing a greater in vitro immunomodulatory ability than BMSCs derived from age-matched donors (Melief et al., 2013), since they are able to partially suppress lymphocytes proliferation, as well as to inhibit differentiation of monocyte-derived immature dendritic cells and NK cell cytotoxic activity (Russell et al., 2016; Valencia et al., 2016). Such effects are likely to depend on both cell contact-dependent mechanisms and paracrine effects through the production of cytokines and various soluble factors that regulate immune cells functions (Sotiroupolou et al., 2006), improve the microenvironment for tissue healing (Burlacu et al., 2013) and exert strong immunosuppressive effects by decreasing inflammatory cytokine production (Zhao et al., 2010). Indeed, higher immunomodulatory potential of ASCs is also related to higher levels of cytokine production (Melief et al., 2013).

These findings contributed to make ASCs a viable option in regenerative medicine and a powerful tool in cell-based therapy for restoring damaged tissues and decreasing inflammatory/immune response, opening the way to their application in the treatment of a wide panel of pathologies, including inflammatory and autoimmune diseases (De Miguel et al., 2012; Scuderi et al., 2013; Onesti et al., 2016). In preclinical studies, ASCs have been successfully used to reduce chronic disability in ischemic stroke in rats (Gutiérrez-Fernández et al., 2013; Oh et al., 2015; Chen et al., 2016), to delay onset and slow disease progression in murine and rat models of multiple sclerosis (Yousefi et al., 2013; Semon et al., 2014; Bowles et al., 2017) and to limit structural changes in the lung parenchyma by reducing inflammation and neutrophils number in the airways in chronic obstructive pulmonary disease in mice and guinea pig models (Ghorbani et al., 2014; Hong et al., 2016). Preclinical studies on ASCs, performed in swine and rodent models, also showed promising results across a wide range of cardiovascular therapeutic applications (Hashemi et al., 2008; Cai et al., 2009; Madonna et al., 2009; Bai et al., 2010; Grimaldi et al., 2013; Sommese et al., 2017), due to both stimulation of angiogenesis and potent anti-inflammatory paracrine effect eventually favoring the cardiac healing process (Gnecchi et al., 2005). ASC-based cellular therapy has been further considered for the treatment of neurodegenerative diseases, including mouse models of Alzheimer’s disease or Parkinson’s disease and amyotrophic lateral sclerosis (ALS) patients (McCoy et al., 2008; Yan et al., 2014; Fontanilla et al., 2015; Staff et al., 2016), as well as, in humans, for immunological disorders, such as graft versus host disease (GVHD) (Yañez et al., 2006; Fang et al., 2007; Tholpady et al., 2009) and autoimmune pathologies, such as type I diabetes mellitus (Vanikar et al., 2010; Lin et al., 2015), systemic sclerosis (Scuderi et al., 2013), rheumatoid arthritis (El-Jawhari et al., 2014; Ueyama et al., 2020) and systemic lupus erythematosus (SLE) (Liang et al., 2010; Park et al., 2015). A consistent number of clinical trials using ASCs are ongoing for the treatment of some of these disorders, even though only some complete clinical results are now available, but the greatest number of human studies are in patients with osteoarthritis and inflammatory bowel disease (IBD) (González et al., 2009a; Sovrea et al., 2019). In particular, multiple Phase I clinical trials assessed the efficacy of intra articular injection of ASCs in improving pain, function and mobility of affected joints, with no major adverse effects (Jo et al., 2014; Pers et al., 2016; Yokota et al., 2017). As for IBD, in a phase III study, ASCs have been shown to be effective and safe for the treatment of complex perianal fistulas in Crohn’s disease patients who did not respond to conventional and/or biological treatments (Panès et al., 2016). The most relevant studies on ASCs-based treatment in different pathologies are summarized in Table 1.

Despite the widespread use of ASCs in cell therapy trials, the pathophysiological mechanisms at the basis of their clinical use have been not yet fully investigated. Here, we focused on the immunomodulatory properties of ASCs, through a comprehensive description of the molecular mechanisms and factors involved and the importance of milieu chemical-physical characteristics. Indeed, a plethora of paracrine signals are involved in ASC-mediated immunomodulation, thus suggesting the potential clinical use of ASC secretome, and the importance of environmental stimuli (culture conditions as well as local in vitro microenvironment) in determining clinical outcome. We also shed light on the potential strategies for optimization of ASCs efficacy in clinical settings, especially those related to boosting immunomodulatory capacity, acting both on local microenvironment and directly on ASCs through genetic or epigenetic regulation of gene expression, and to improving ASC characterization in order to standardize clinical outcome.

**IMMUNOMODULATORY PROPERTIES OF ASCs**

ASCs are considered more powerful suppressors of immune response than mesenchymal stem cells (MSCs) derived from

---

1. www.clinicaltrials.gov
### TABLE 1 | The most relevant studies on ASCs-based treatment in different pathologies are highlighted, indicating the type of treatment and the cellular and molecular mechanisms involved in ASCs or ASC secretome effect in vivo.

| Pathology                                      | ASCs-based treatment                                                                 | Cellular and molecular mechanisms                                                                                                                                                                                                                     | References                                                                 |
|------------------------------------------------|---------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Acute Myocardial Infarction                    | ASCs conditioned medium                                                               | Pro-survival and anti-apoptotic effects on cardiomyocytes; anti-inflammatory and pro-angiogenic potential (VEGF, HGF, PGF, PGE-2, FGF-2, TGF-β, IL-10, NO, NGF, Ang-1 and Ang-2, IGF-1, miR-31, miR-126 and miR-301a); Inhibition of fibrosis and cardiac remodeling (VEGF, HGF, MCP-1, TIMP-1 and TIMP-4) | Valina et al., 2007; Hashemi et al., 2008; Cai et al., 2009; Bai et al., 2010; Grimaldi et al., 2013; Naaijens et al., 2014; Sommese et al., 2017 |
| Cardiovascular diseases (e.g. acute ischemic stroke) | ASCs (intra-arterial and intravenous transplantation) ASCs exosomes                   | Attenuated inflammation and enhanced endogenous neurogenesis; reduction in cell death, increase in cellular proliferation, neurogenesis, oligodendrogeneration, synaptogenesis and angiogenesis markers; suppression of inflammation, generation of ROS and oxidative stress | Madonna et al., 2009; Gutiérrez-Fernández et al., 2013; Oh et al., 2015; Chen et al., 2016 |
| Chronic Obstructive Pulmonary Disease          | ASCs (intra-tracheal and intravenous delivery)                                        | Reduction of oxidative damage; restored imbalance of protease/anti-protease ratio, anti-apoptotic activity and increased production of growth factors (HGF, FGF-2, VEGF); protection from lung damage | Ghorbani et al., 2014; Hong et al., 2016 |
| Multiple Sclerosis                             | ASCs (intraperitoneal/intravenous injection) ASCs conditioned medium                  | Pathological features diminished, suppression of IFNγ and IL-12 in the sera of EAE mice; down-regulation of splenocytes proliferation and IL-17 secretion, alleviation of clinical scores severity; increased production of TGFβ1, IL-4, IL-10, NO, and IDO by splenocytes | Yousfi et al., 2013; Semon et al., 2014; Bowles et al., 2017 |
| Parkinson’s disease                            | ASCs (intra-striatal injection)                                                       | Production of growth factors known to promote dopaminergic survival and neuroprotection at the lesion site                                                                                       | McCoy et al., 2008 |
| Alzheimer’s disease                             | ASCs (intra-hippocampal injection)                                                    | Reduced oxidative stress, alleviated cognitive impairment and enhanced neurogenesis                                                                                                             | Yan et al., 2014 |
| Amyotrophic Lateral Sclerosis                  | ASCs conditioned medium                                                               | NGF-mediated neuroprotection: high motor neuron counts, less activation of microglia and astrocytes, reduced levels of phosphorylated p38 (inflammation and neural death) in the spinal cord; mild temporary subjective clinical improvements (phase I clinical trial) | Fontanilla et al., 2015; Staff et al., 2016 |
| Systemic Sclerosis                             | ASCs (intra-dermal injection in hyaluronic acid solution)                             | Improvement in tightening of the skin due to anti-inflammatory soluble factors secretion and expansion of regulatory T-cells                                                                     | Scuderi et al., 2013 |
| Rheumatoid Arthritis                           | ASCs (3D-spheroids intra-articular injection)                                          | Suppression of proliferation and migration of activated inflammatory cells and down-regulation of inflammatory cytokines; suppression of synovial cell and macrophage function, upregulation of TSG-6 and TGFβ1 | El-Jawhari et al., 2014; Ueyama et al., 2020 |
| Systemic Lupus Erythematosus                   | ASCs (intravenous injection)                                                          | Immuno-modulatory effects: decreased serum levels of immunoglobulins (IgG, IgG1, IgM, and IgE) and autoantibodies; decreased number of Th1 cells and Th17 cells; increased Foxp3- expressing Tregs, which suppress autoimmune processes and maintain peripheral tolerance | Park et al., 2015 |
| Type I Diabetes                                | ASCs (intra-peritoneal injection)                                                      | Recovered levels of glucose, cholesterol, triglycerides, urea nitrogen, and creatinine; alleviation of renal damage through reduction of oxidative stress; decreased TNF-α, IL-1β, and IL-6 cytokine levels and inhibition of the MAPK signalling pathway; improved pancreatic expression of insulin and pancreatic duodenal homeobox 1 (Pdx1); attenuation of Th1 immune response | Vankar et al., 2010; Lin et al., 2015 |
| Inflammatory Bowel Disease (e.g. Crohn’s disease) | ASCs (local application and systemic infusion)                                         | Anti-inflammatory effect; down-regulation of Th1-type cytokines expression, IFN-γ and TNF-α, increase of the number of CD4 T cells producing IL-10; proliferation, angiogenesis and remodeling stimulation during the healing process | González et al., 2009a; Panés et al., 2016; Sovrea et al., 2019 |
| GvHD                                           | ASCs (systemic infusion)                                                              | Prevention of allogeneic T-cells proliferation; suppression of the proliferation of T cells induced either by mitogens or allogeneic cells; secretion of soluble factors with immuno-suppressive effects; inhibition of inflammatory cytokines production (TNF-α, IFN-γ, and IL-12) of stimulated T cells | Yahez et al., 2006; Fang et al., 2007; Tholpady et al., 2009 |
different tissue sources, including trabecular bone, bone marrow, dental pulp, and umbilical cord (Ribeiro et al., 2013; Nancarrow-Lei et al., 2017). In particular, ASCs immunomodulatory effects exceed that of bone marrow MSCs, which are currently considered the gold standard, due to a higher level of cytokines secretion (Melief et al., 2013). Indeed, a small number of highly metabolically active ASCs secrete higher amount of immune suppressive cytokines, such as IL-6 and transforming growth factor-β1 (TGF-β1) (Soleymaninejadian et al., 2012; Melief et al., 2013; Montespan et al., 2014). In the allogeneic setting, where HLA mismatch occurs, such as in mixed lymphocyte reactions (MLR), ASCs suppress T cell allo-proliferation, because they express low levels of HMC-I, are deficient in major HMC-II and in costimulatory molecules, like CD80, CD86, CD40 and its ligand, CD40L (Strioga et al., 2012; Machado et al., 2013). ASCs also inhibit B lymphocyte proliferation and differentiation into plasmocytic cells, unable to produce antibodies (Franqueza et al., 2015). This characteristic could be important for their use in the treatment of B-cell mediated disorders and GVHHD during organ transplantation (Franqueza et al., 2012, 2015). B-cells are antigen-presenting cells (APCs) that produce pro- and anti-inflammatory cytokines. When both ASCs and B-cells are in a co-culture setting, the former cells have an inhibitory effect on the chemotactic properties of the latter, by downregulating chemokine receptors on the B cells, such as CXCR4, CXCR5 (Cocrineo et al., 2006). In contrast, ASCs may induce proliferation of a subset of CD5 + regulatory B cells that secrete immunosuppressive IL-10. This cytokine inhibits the production of other inflammatory cytokines by activated T cells and could be relevant in the therapeutic treatment of autoimmune diseases (Kalampokis et al., 2013; Peng et al., 2015). In addition, a negative feedback loop between activated T cells-producing interferon γ (IFNγ) and ASCs exists (Machado et al., 2013). The secretion of IFNγ primes ASCs against T cells proliferation (Machado et al., 2013). Consequently, ASCs are able to escape immune surveillance and simultaneously, they are endowed with ability to self-renew and differentiate into other cell-like types, hence facilitating allogeneic tissue regeneration (Machado et al., 2013; Bateman et al., 2018).

A relevant example of the immunomodulatory potential of allogeneic ASCs is the injection of human ASCs (hASCs) in a DBA/1 mouse model with collagen-induced arthritis (González et al., 2009b). Administration of hASCs provoked a decrease of several inflammatory cytokines and chemokines, resulting in reduction of antigen-specific Th1/Th17 cell proliferation. In contrast, IL-10 production was induced in lymph nodes and joints. Yet, antigen-specific Tregs were also produced and as a consequence, self-reactive T effector responses were suppressed (González et al., 2009b).

The stromal vascular fraction (SVF) of an adipose tissue contains not only ASCs but also different cell types, such as endothelial cells, pericytes, lymphocytes, monocytes macrophages, fibroblasts, and smooth muscle cells (Dominici et al., 2006; Bourin et al., 2013; Nürnbergber et al., 2019). In vitro, freshly isolated SVF containing ASCs secrete trophic and pro-regenerative factors, such as cytokines, growth factors, anti-inflammatory factors and extracellular vesicles harboring proteins or even microRNAs, collectively known as secretome (Fu et al., 2017). In fact, several studies have shown that the paracrine effects of ASCs and not the cells themselves, are pivotal players for tissue repair along with angiogenic and immunomodulatory properties occurring at the site of the damaged tissue (Tögel et al., 2005; Krampera, 2011; Eleuteri and Fierabracci, 2019). For example, high levels of two immunomodulatory mediators, indoleamine-pyrrole 2,3-dioxygenase (IDO) and Prostaglandin E2 (PGE2), were detected at 24 h in the supernatants from freshly isolated SVF (Nürnbergber et al., 2019). It is known thatIDO is an immunomodulatory enzyme produced by macrophages with immunosuppressive functions for T-cells and natural killers (NK). Moreover, ASCs inhibit maturation of dendritic cells and induce macrophage to differentiate into anti-inflammatory regulatory cells (Kim and Hematti, 2009; Sun et al., 2019). PGE2 is a major mediator of ASCs immunomodulation having multiple functions (Gao et al., 2016; Najar et al., 2016; Kote et al., 2017). One of these is the induction of IL-10 by macrophages, which in turn inhibits NK cells and T helper cells (Eleuteri and Fierabracci, 2019). Human leukocyte antigen-G5 (HLA-G5), galectins and programmed cell death ligand (PD-L1) are other factors involved in immunomodulation by ASCs (Gieseke et al., 2010; Yang et al., 2012; Zhou et al., 2018). HLA-G5 is a non-classical MHC- class I molecule, expressed on the surface of ASCs, which exert immunogenic tolerance through inhibition of NK, allogeneic T-cell responses and dendritic cells (DC) (Nasef et al., 2007). Galectin-1 and PD-L1 are negative regulators of immune responses, known as immune checkpoints (ICs) and are expressed on the surface of ASCs (Najar et al., 2010; Zhou et al., 2018). A milestone study conducted by Sheng et al. (2008) showed that PD-L1 expression is induced on the surface of MSCs isolated from mouse bone marrow by T cell secreted IFNγ. This study provided further insights as to the role of PD-L1 and other ICs in the immunosuppressive potential of ASCs. Zhou et al. (2018) co-cultured human ASCs that express PD-L1 and galectin 9 (Gal-9), with allogeneic peripheral blood mononuclear cells (PBMCs). The two ICs bound the corresponding ligands on the T cell, PD-L1 to PD-1 and Gal-9 to TIMP-3. In these experimental conditions, ASCs evoked T cell suppression through inhibition of the transcription factor NF-κB activation in TCR-stimulated T cells via the PD-L1/PD-1 and Gal-9/TIMP-3 pathways (Zhou et al., 2018). However, the interaction between ICs and ASCs has not been explored fully and this could be an exciting area of further investigation.

The immunosuppressive ability of ASCs is both dose and cell passage dependent (Waldner et al., 2018). After the isolation of ASCs from adipose tissues, these cells undergo multiple culture passages in vitro, since significant numbers are needed for autologous clinical applications. Critically, during serial passage, ASCs become more differentiated and simultaneously they start losing their immunosuppressive properties. For instance, HLA-G expression dramatically decreases in adult ASCs (Teklemariam et al., 2014). Furthermore, the expression of HLA class-II and the other co-stimulatory molecules, CD80 and CD86, increases in very late passed ASCs differentiating in mature adipocytes then causing T-cell proliferation in
a direct contact-dependent manner (Poloni et al., 2015). Changes in cytokine milieu chemical-physical characteristics with subsequent passages of ASCs, also need to be taken into consideration (Leto Barone et al., 2013). Therapeutic applications of ASCs are influenced by hypoxic conditions, 3D cell culture scaffolds and growth factors added in culture, that could modify cell proliferation and ultimately their secretome (Madrigal et al., 2014). Once the ASCs or their secretome are injected into an injured tissue, they might interact with an unfavorable microenvironment, provoking different therapeutic responses than expected. For this reason, it has been suggested to evaluate the inflammatory status and the disease stage of a patient prior to the recruitment and treatment for clinical trials (Eleuteri and Fierabracci, 2019). The safety and timing of ASCs administration are also important requirements for the favorable outcome of cell therapy (Leto Barone et al., 2013).

**APPROACHES FOR OPTIMIZATION OF ASCs IMMUNOMODULATORY EFFICACY**

Although ASCs demonstrated higher immunomodulatory potential with respect to other kind of MSCs (Ivanova-Todorova et al., 2009; Najar et al., 2010, 2013; Ribeiro et al., 2013), their use as a gold standard for cell therapy of immune-related disorders needs further elucidations. Once ASCs are isolated and expanded in 2D cultures *in vitro*, they lose the stem cell niche environmental protection and sustainment, which is important to maintain ASC pluriotropy, but also their immunomodulatory properties (Jones and Wagers, 2008; Napoli et al., 2008; Voog and Jones, 2010; Kaewsuwan et al., 2012). To date, different ASC enhancement strategies have been proposed, based on external stimuli changes and interventions focused on cells themselves.

An intuitive solution could be to directly recapitulate stem cell niche setting through 3D cultures. In these multicellular structures, adherent cells aggregate with each other through suspension culture system, generating spheroids (Kapur et al., 2012; Daquiniag et al., 2013; Duval et al., 2017). As such, paracrine signaling is promoted by the proximity of the cells and the interaction of ASCs with extra cellular matrix (ECM)-like structures or other cell types (co-cultures) increases the secretion level of anti-inflammatory and pro-angiogenic molecules (Amos et al., 2010; Bartosh et al., 2010; Mineda et al., 2015). The employment of ASCs spheroids in the treatment of experimental *in vivo* disease models such as elastase-induced emphysema, hindlimb ischemia, acute kidney ischemia and diabetic skin wound healing demonstrated encouraging results regarding differentiation, pro-angiogenic and regenerative capacity of ASCs (Amos et al., 2010; Xu et al., 2016; Cho et al., 2017; Park et al., 2017). Currently, chitosan-coated culture plates, concaved bottom wells, ultra-low attachment plates, the hanging drop technique and spinner flask are the most widely used methods for spheroid generation (Duval et al., 2017). In particular, Regmi et al. (2019) showed that 3D-ASCs obtained through hanging drop method have enhanced immunomodulatory effects in systemic inflammatory response syndrome frequently observed in severe fulminant hepatic failure. Limitations of 3D spheroids may be related to the fact that *in vitro* nutrients and oxygen may be less available at the core of the 3D spheres, inducing necrosis and altering ASCs functions (Cheng et al., 2013; Edmondson et al., 2014). An alternative strategy to obtain 3D ASCs cell cultures is simulate microgravity in a Rotary Cell Culture System (RCCS) bioreactor (Yu et al., 2011; Kang et al., 2015). The RCCS system can be useful to overcome the oxygen and nutrient gradient problems (Costantini et al., 2019). Anyway, in these experimental conditions, some other factors involved in immunomodulation could be harder to control. An easier strategy may be to dissect these mechanisms and apply single level interventions.

As for the external stimuli, it has been demonstrated that the presence of growth factors in the culture medium could enhance ASCs differentiation (Ceccarelli et al., 2018). Likewise, pre-conditioning of ASCs with cytokines or other bioactive molecules represents one of the main approaches to boost ASCs immune regulatory functions before their therapeutic administration. IFN-γ and tumor necrosis factor α (TNF-α) are the major inflammatory cytokines used in MSC functional enhancement. After IFN-γ priming, ASCs showed overexpression of IDO, together with Cyclooxygenase 2 (COX2), TGF-β and Hepatocyte Growth Factor (HGF) (Ryan et al., 2007; Delarosa et al., 2009; Kronsteiner et al., 2011), central factors in immunological tolerance and anti-inflammatory mechanisms. TNF-α treatment, not only increased the production of IDO, PGE2, and HGF, but also of the pro-inflammatory cytokines IL-6 and IL-8, promoting endothelial progenitor cell migration and angiogenesis (Crop et al., 2010; Kwon et al., 2013), a primary goal of regenerative medicine. Furthermore, ASCs primed with IL-17, TNF-α, and IFN-γ have increased T cell immunosuppressive capacity mediated by inducible nitric oxide synthase (iNOS) production and have been shown to reduce inflammation and tissue injury in murine model of hepatitis (Han et al., 2014). An additional strategy is the pre-conditioning of ASCs with toll-like receptors (TLRs) agonists. ASCs express TLRs, cell membrane sensors that play a pivotal role in innate immune system mechanisms (Hwa Cho et al., 2006; Lombardo et al., 2009). Although TLRs agonists seem to be mainly implicated in ASCs multi-lineage differentiation capacity (Seo et al., 2019), studies demonstrated that TLR3 activation might induce suppressive phenotype (Hwa Cho et al., 2006; Bunnell et al., 2010; Waterman et al., 2010). By mimicking an *in vivo* inflammatory milieu, the combination of cytokines and TLRs ligands seemed to generate additive effects on MSCs immunomodulatory properties, enhancing their therapeutic efficacy more than the use of a single molecular category (Gu et al., 2015). The downside of this approach may be that cytokine priming can confer immunogenicity to the ASCs, exposing them to host immune responses (Galipeau, 2017).

To date, only few studies have been performed on the induction of epigenetic modification to enhance immunomodulatory capacity of ASCs. Recent findings have provided insight into the exposure to 5-Aza-2′-deoxycytidine (5-AZA-dC) during *in vitro* expansion of ASCs that resulted in the upregulation of HLA-G gene, whose sustained expression is crucial to maintain immunomodulatory capabilities in adult stem cells (Teklemariam et al., 2014). MicroRNAs are also implicated in epigenetic regulation of ASCs immunomodulatory
properties, as proven by Wang et al. (2019) in a mouse model of colitis. Mysm1, a histone deubiquitinase, is induced by TNF-α and IFNγ in ASCs and promotes miR-150 transcription, which enhances iNOS production. Nitric oxide is catalyzed by iNOS that is essential for the immunosuppressive capacity of ASCs. Therefore, miRNA-based strategies could be promising in enhancing therapeutic ASCs efficacy. Because both epigenetic modulators and ASCs have common aspects in immune modulation (Lee et al., 2015; Sabia et al., 2017), their respective contributions should be established and it is important to pay attention to possible cross-interactions.

A straightforward approach is to modify MSCs in order to increase the expression of genes such as IL-10 (Min et al., 2007), HGF (Bian et al., 2009), IDO (Kim et al., 2018), and FOXP3 (Qi et al., 2015) to obtain therapeutic anti-inflammatory effects. Genetically engineered ASCs have demonstrated efficacy in the treatment of inflammatory disease in vivo. Several studies reported the clinical success of different approaches to ASC genetic modification. The administration of human ASCs transduced with a bicistronic lentiviral vector encoding mouse IL-4 in C57Bl/6 mice with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, results in a reduction of antigen-specific T-cell responses, thus attenuating clinical disease (Payne et al., 2012). Human ASCs transduced with a lentiviral vector for CTLA-4 Ig overexpression, when transplanted into a mouse model of sustained severe collagen induced arthritis, are able to enable CTLA-4 binding to CD28, which results in the induction of T-cell clonal anergy and the amelioration of autoimmune disease (Choi et al., 2016). The introduction of IL-1 receptor-like-1 (sST2), a decoy receptor for IL-33, in ASCs using a bicistronic lentiviral vector encoding the sST2–C-terminal promotes inflammation suppression and alleviation of the pathological events in acute lung injury (ALI) mouse model (Martínez-González et al., 2013). Furthermore, overexpression of IL-35, a recently discovered anti-inflammatory cytokine, represent a powerful tool to potentiate ASC-based cell therapy approach for auto-immune diseases. Results obtained by Zhao et al. demonstrated that murine ASCs transduced with a recombinant lentiviral vector to overexpress IL-35 are able to decrease CD4+ T-cell proliferation and IL-17 secretion in an in vitro co-culture model (Zhao et al., 2017).

THE ROAD AHEAD IN IMMUNOMODULATORY POTENTIAL OF ASCs

Much effort has been done regarding the use of autologous versus allogeneic cells for in vivo applications (Feisst et al., 2015), with the first being preferred especially for chronic pathologies since the time required for the isolation and expansion of cells is not a limit given to the non-acute nature of the diseases. However, by using autologous ASCs there were consistent variations in clinical outcome, since cell characteristics may vary between patients, not only according to biological factors as age, sex, body mass index but also depending upon the disease (Varghese et al., 2017).
In this regard, contradictory results are available about the properties of ASCs isolated from patients affected by autoimmune and chronic inflammatory diseases. For example, some reports demonstrated that ASCs from patients affected by systemic sclerosis show the same phenotypical and functional characteristics of their healthy counterparts (Scuderi et al., 2013; Capelli et al., 2017; Velier et al., 2019), while Griffin et al. (2017) observed that ASCs from sclerodermic patients showed identical phenotype and differentiation capacity of those from healthy donors, but displayed reduced proliferation and migration capacity. Whilst, the presence of cardiovascular risk factors in cardiac patients seems to reduce ASC pluripotency and self-renewal, thus discouraging their autologous use in the clinical setting (Dimmeler and Leri, 2008; Krawiec et al., 2016). In particular, microenvironmental factors and metabolic disorders may impact the functionality of these cells. ASCs derived from obese subjects and from patients affected by type 2 diabetes showed increased expression of inflammatory markers with respect to those derived from lean donors, as well as a remarkable reduction in their immunosuppressive activities (Serena et al., 2016). Moreover, ASCs from obese patients also display an impaired angiogenic potential (Oñate et al., 2012, 2013). Other groups observed that diabetes did not alter ASC isolation efficiency, growth curves and angiogenic potential, but ASCs from diabetic patients showed a delay in the acquisition of endothelial cell markers, thus suggesting an impaired differentiation (Policha et al., 2014).

The use of allogeneic stem cells may overcome these limitations, but it has to be considered that adipose tissue availability is dependent on surgical procedures, thus limiting the occurrence of overall healthy donors. More attention should be also paid to the origin of allogeneic ASCs, since several studies underlined a cellular and molecular variability depending on the donor age, sex and tissue source even under similar genetic and environmental conditions (Shu et al., 2012; Bodle et al., 2014; Ock et al., 2016; Abbo et al., 2017). In particular, ASCs derived from different donors might have significant variations in the chemical-physical characteristics of their secretome (Alicka et al., 2019), thus affecting their immunomodulatory capacity (Bunnell et al., 2010). In order to avoid donor-to-donor heterogeneity, a strategy with pooled ASCs of different allogeneic donors could be proposed, as previously reported for BMSCs (Kuçi et al., 2016), but immunogenic stimuli could increase (Ankrum et al., 2014; Patrikoski et al., 2014). Indeed, although ASCs have been shown to possess a low immunogenic profile, the potential immunogenicity of allogeneic cells, which might determine their rejection after infusion, cannot be excluded. In fact, it has been observed that the immunogenicity of ASCs decreases with cell passaging, so that cells at low passages are more immunogenic than those at higher passages (McIntosh et al., 2006), and that ASCs are not fully immune privileged, since they elicit both humoral and cellular immune response in vivo, depending on the microenvironment (Ankrum et al., 2014). Also ASC differentiation may alter their immunogenic phenotype, increasing HLA class-I and HLA class-II expression (García-Sancho et al., 2017), as well as culturing condition (e.g., use of human serum or serum-free conditions) (Patrikoski et al., 2014).

**CONCLUSION**

ASCs represent a valuable treatment option for a wide range of inflammatory or autoimmune diseases, which therapeutic efficacy relies primarily on immunomodulatory activities mediate by paracrine effects. An increasing number of preclinical studies and clinical trials are being developed to assess ASCs safety and efficacy. However, although there are promising results and increasing knowledge in the in vivo applications of ASCs, unfortunately, several clinical trials have failed due to differences in experimental protocols, read-out, animal models and variability in ASCs characteristics. So, the clinical translation of ASCs still requires a proper validation in large controlled trials. For a more successful outcome of ASC-based therapies, thorough investigations with more standardized protocols are urgently required, as well as a better understanding of ASC immunomodulatory network and the identification of key molecules and/or regulatory mechanisms responsible for ASC effects in chronic inflammatory diseases.

The in-depth analysis of the potential strategies aimed to boost ASC-mediated immunomodulation (summarized in Figure 1) will foster new targeted approaches for cell therapy applications in the field of immune diseases. Yet, such interventions need to be accurately considered, since any alteration of immune system sensitivity can be dangerous: weakening the capacity of recognize transformed cells or pathogens, or vice versa exacerbating immune response, could lead to adverse events. As for genetic modification, the engineered cells persisting in the host could generate undesirable effects, such as potential tumorigenicity related to genetic instability (Heslop et al., 2015; Neri, 2019).

Finally, standardization of both ASC and patient’s characteristics prior to clinical use are necessary to avoid that the donor phenotype might compromise their immunomodulatory properties, thus impairing their therapeutic efficacy.

**AUTHOR CONTRIBUTIONS**

SC conceived the review and wrote the manuscript. PP and EA revised the literature and helped to writing the manuscript. CN edited the manuscript. CM supervised the overall project and edited the manuscript. All authors had the opportunity to discuss and comment on the manuscript.

**FUNDING**

This research was conducted with the help of the PRIN 2017 supporting grant no. F8ZB89.
REFERENCES

Abbo, O., Taurand, M., Monsarrat, P., Raymond, I., Arnaud, E., De Barros, S., et al. (2017). Comparison between pediatric and adult adipose mesenchymal stromal cells. Cytotherapy 19, 395–407. doi: 10.1016/j.jcyt.2016.11.012

Alicka, M., Major, P., Wysocki, M., and Maryc, K. (2019). Adipose-derived mesenchymal stem cells isolated from patients with type 2 diabetes show reduced "Stenness" through an altered secretome profile, impaired antioxidant protection, and mitochondrial dynamics deterioration. J. Clin. Med. 8:E765. doi: 10.3390/jcm8060765

Amos, P. J., Kapur, S. K., Stapor, P. C., Shang, H., Bekiranov, S., Krugel, M., et al. (2010). Human adipose-derived stromal cells accelerate diabetic wound healing: impact of cell formulation and delivery. Tissue Eng. Part A 16, 1595–1606. doi: 10.1089/ten.TEA.2009.0616

Ankrum, J. A., Ong, J. F., and Karp, J. M. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32, 252–260. doi: 10.1038/nbt.2816

Aurich, H., Sgoda, M., Kaltwasser, P., Vetter, M., Weise, A., Liehr, T., et al. (2009). Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 58, 570–581. doi: 10.1136/gut.2008.154880

Bai, X., Yan, Y., Song, Y. H., So, J. H., Shih, C. Y., Wang, Y., Yan, Y., et al. (2016). Effects of transplantation of CTLL4g-overexpressing adipose tissue-derived mesenchymal stem cells in mice with sustained severe rheumatoid arthritis. Cell Transplant. 25, 243–259. doi: 10.3727/096368915X688470

Bartosh, T. J., Ylöstalo, J. H., Mohammadipoor, A., Bazhanov, N., Coble, K., Claypool, K., et al. (2010). Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their anti-inflammatory properties. Proc. Natl. Acad. Sci. USA 107, 13724–13729. doi: 10.1073/pnas.1008117107

Bateman, M. E., Strong, A. L., Gimble, J. M., and Bunnell, B. A. (2018). Concise review: using fat to fight disease: a systematic review of nonhomologous adipose-derived stromal/stem cell therapies. Stem Cells 36, 1311–1328. doi: 10.1002/stem.2847

Bian, L., Guo, Z. K., Wang, H. X., Wang, J. S., Wang, H., Li, Q. F., et al. (2009). In vitro and in vivo immunosuppressive characteristics of hepatocyte growth factor-modified murine mesenchymal stem cells. In Vivo 23, 21–27.

Bodle, J. C., Teeter, S. D., Hiluck, B. R., Hardin, J. W., Bernacki, S. H., and Loboa, E. G. (2014). Age-related effects on the potency of human adipose-derived stem cells: creation and evaluation of superlots and implications for musculoskeletal tissue engineering applications. Tissue Eng. Part C Methods 20, 972–983. doi: 10.1089/tenc.2013.0683

Bourin, P., Bunnell, B. A., Castella, L., Dominici, M., Katz, A. J., March, K. L., et al. (2013). Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International So. Cytotherapy 15, 641–648. doi: 10.1016/j.jcyt.2013.02.006

Bowles, A. C., Strong, A. L., Wise, R. M., Thomas, R. C., Gerstein, B. Y., Dutreil, J., et al. (2009). Effects of transplantation of CTLL4g-overexpressing adipose tissue-derived mesenchymal stem cells in mice with sustained severe rheumatoid arthritis. Cell Transplant. 25, 243–259. doi: 10.3727/096368915X688470

Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367–372.

Costantini, D., Overi, D., Casadei, L., Cardina, V., Nevi, L., Carpin, G., et al. (2019). Simulated microgravity promotes the formation of tridimensional cultures and stimulates pluripotency and a glycolytic metabolism in human hepatic and biliary tree/stem/progenitor cells. Sci. Rep. 9:5559. doi: 10.1038/s41598-019-41908-5

Cropp, M. J., Baan, C. C., Kooi, E. S., Ijzermans, J. N. M., Pescatori, M., Stubbs, A. P., et al. (2010). Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin. Exp. Immunol. 162, 474–486. doi: 10.1111/j.1600-0625.2010.04256.x

Dai, R., Wang, Z., Samanipour, R., Koo, K. I., and Kim, K. (2016). Adipose-derived stem cells for tissue engineering and regenerative medicine applications. Stem Cells Int. 2016:6737345. doi: 10.1155/2016/6737345

Daquinah, A. C., Souza, G. R., and Kolonin, M. G. (2013). Adipose tissue engineering in three-dimensional levitation tissue culture system based on magnetic nanoparticles. Tissue Eng. Part C Methods 19, 336–344. doi: 10.1089/ten.TEC.2012.0198

Dave, S. D., Vanikar, A. V., and Trivedi, H. L. (2014). In-vitro generation of human adipose tissue derived insulin secreting cells: up-regulation of Pax-6, Ipf-1 and Isp-1. Cytotechnology 66, 299–307. doi: 10.1007/s10616-013-9573-3

De Miguel, M. P., Fuentes-Julian, S., Blazquez-Martinez, A., Pascual, C. Y., Aller, M. A., Arias, J., et al. (2012). Immunosuppressive properties of mesenchymal stem cells: advances and applications. Curr. Mol. Med. 12, 574–591.

Delarosa, O., Lombardo, E., Beraza, A., Mancheño-Corvo, P., Ramirez, C., Menta, R., et al. (2009). Requirement of IFN-γ-mediated induction of CD94/2-DIOXYGENASE expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng. Part A 15, 2795–2806. doi: 10.1089/ten.tea.2008.0630

Dimmeler, S., and Leri, A. (2008). Aging and disease as modifiers of efficacy of cell therapy. Circ. Res. 102, 1319–1330. doi: 10.1161/CIRCRESAHA.107.159743

Dominici, M., Le Blanc, K., Mueller, L., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., et al. (2006). Minimal criteria for defining multipotent mesenchymal stem cells: the International Society for Cellular Therapy position statement. Cytotherapy 8, 315–317. doi: 10.1080/14785470600585500

Duval, K., Grover, H., Han, L. H., Mou, Y., Pegoraro, A. F., Fredberg, J., et al. (2017). Modeling physiological events in 2D vs 3D cell culture. Physiology 32, 266–277. doi: 10.1152/physiol.00363.2016

Edmonson, R., Broglie, J. J., Adcock, A. F., and Yang, L. (2014). Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev. Technol. 12, 207–218. doi: 10.1089/adt.2014.573

Eleuteri, S., and Fierabracci, A. (2019). Insights into the secretome of mesenchymal stem cells and its potential applications. Int. J. Mol. Sci. 20:E4597. doi: 10.3390/ijms20184597
El-Jawhari, J. J., El-Sherbiny, Y. M., Jones, E. A., and McGonagle, D. (2014). Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM 107, 505–514. doi: 10.1093/qjmed/hcu033

Fang, B., Song, Y., Lin, Q., Zhang, Y., Cao, Y., Zhao, R. C., et al. (2007). Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr. Transplant. 11, 814–817. doi: 10.1111/j.1399-3046.2007.00780.x

Feist, V., Meidinger, S., and Locke, M. B. (2015). From bench to bedside: use of human adipose-derived stem cells. Stem Cells Cloning 8, 149–162. doi: 10.2147/SCCAA.S64373

Fontanilla, C. V., Gu, H., Liu, Q., Zhu, T. Z., Zhou, C., Johnstone, B. H., et al. (2015). Concise review: workshop review: understanding and assessing the risks of stem cell-based therapies. Stem Cells Transl. Med. 4, 389–400. doi: 10.5966/sctm.2014-0011

Hong, Y., Kim, Y. S., Hong, S. H., and Oh, Y. M. (2016). Therapeutic effects of adipose-derived stem cells pretreated with pioglitazone in an emphysema mouse model. Exp. Mol. Med. 48, e266. doi: 10.1038/emmm.2016.93

Woo Chao, H., Bae, Y. C., and Jung, J. S. (2006). Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 24, 2744–2752. doi: 10.1634/stemcells.2006-0189

Franquesa, M., Mensah, F. K., Huizinga, R., Strini, T., Boon, L., Lombardo, E., et al. (2012). Human adipose tissue-derived stromal cells maintain proliferative, synthetic and multipotential properties when suspension cultured as self-assembling three-dimensional spheroids. Biofabrication 4:025004. doi: 10.1088/1758-5082/4/2/025004

Kapur, S. K., Wang, X., Shang, H., Yun, S., Xi, L., Feng, G., et al. (2012). Human adipose stem cells maintain proliferative, synthetic and multipotential properties when suspension cultured as self-assembling spheroids. Biofabrication 4:11. doi: 10.1186/scrt159

Kim, D. S., Jang, I. K., Lee, W. H., Kim, Y. J., Lee, D. H., Lee, J. W., et al. (2018). Enhanced immunosuppressive properties of human mesenchymal stem cells primed by interferon-y. El BioMedicine 28, 261–273. doi: 10.1016/j.ebiom.2018.01.002

Kim, J., and Hematti, P. (2009). Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 37, 1445–1453. doi: 10.1016/j.exphem.2009.09.004

Kota, D. J., Prabhakara, K. S., Toledano-Furman, N., Bhattarai, D., Chen, Q., DiCarlo, B., et al. (2017). Prostaglandin E2 indicates therapeutic efficacy of mesenchymal stem cells in experimental traumatic brain injury. Stem Cells 35, 1416–1430. doi: 10.1002/stem.2603

Kroemer, M. (2011). Mesenchymal stem cell licensing: a multistep process. Leukemia 25, 1408–1414. doi: 10.1038/leu.2011.108

Krawiec, J. T., Weinbaum, J. S., Liao, H. T., Ramaswamy, A. K., Pezzone, D. J., Josowitz, A. D., et al. (2016). In vivo functional evaluation of tissue-engineered vascular grafts fabricated using human adipose-derived stem cells from high cardiovascular risk populations. Tissue Eng. Part A 22, 765–775. doi: 10.1089/ten.TEA.2015.0379

Kronstein, B., Wolbank, S., Peterbauer, A., Hackl, C., Redl, H., Van Griensven, M., et al. (2011). Human mesenchymal stem cells from adipose tissue and...
ammonium influence T-cells depending on stimulation method and presence of other immune cells. Stem Cells Dev. 20, 2115–2126. doi: 10.1089/scd.2011.0031
Kucı, Z., Bönig, H., Kreynenberg, H., Bunos, M., Jauch, A., Janssen, J. W. G., et al. (2016). Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. Haematologica 101, 985–994. doi: 10.3324/haematol.2015.140368
Kwon, Y. W., Heo, S. C., Jeong, G. O., Yoon, J. W., Mo, W. M., Lee, M. J., et al. (2013). Tumor necrosis factor-a-activated mesenchymal stem cells promote endothelial progenitor cell homing and angiogenesis. Biochim. Biophys. Acta 1832, 2136–2144. doi: 10.1016/j.bjbas.2013.08.002
Lee, S., Persson, P., and Mathews, R. D. (2015). an us cr i p t A ce pt us cr i p t A ce pt ed. Rev. Financ. Stud. 29, 2341–2386.
Leto Barone, A. A., Khalifian, S., Lee, W. P. A., and Brandacher, G. (2013). Immunomodulatory effects of adipose-derived stem cells: Fact or fiction? Biomed Res. Int. 2103:383685. doi: 10.1155/2013/383685
Li, X., Ma, T., Sun, J., Shen, M., Xue, X., Chen, Y., et al. (2019). Harnessing the secretome of adipose-derived stem cells in the treatment of ischemic heart diseases. Stem Cell Res. Ther. 10:196. doi: 10.1186/s13287-019-1289-7
Liang, J., Zhang, H., Hua, B., Wang, H., Lu, L., Shi, S., et al. (2010). Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann. Rheum. Dis. 69, 1423–1429. doi: 10.1136/ard.2009.124363
Lin, H. P., Chan, T. M., Fu, R. H., Chuu, C. P., Chiu, S. C., Tseng, Y. H., et al. (2014). Evaluation of phenotypic, functional and molecular characteristics of adipose tissue. Cell Transplant. 29, 521–532. doi: 10.3727/096369914X686977
Lombardo, E., Delarosa, O., Mancheño-Corvo, P., Menta, R., Ramirez, C., and Büscher, D. (2009). Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunomodulation and immunosuppressive potential. Tissue Eng Part A 15, 1579–1589. doi: 10.1089/ten.tea.2008.0340
Machado, C. D., da Silva Telles, P. D., and Nascimento, I. L. O. (2013). Immunological characteristics of mesenchymal stem cells. Rev. Bras. Hematol. Hemoter. 35, 62–67. doi: 10.15161/1561-8484.20130017
Madonna, R., Geng, Y. J., and De Caterina, R. (2009). Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler. Thromb. Vasc. Biol. 29, 1723–1729. doi: 10.1161/ATVBAHA.109.181779
Madrigal, M., Rao, K. S., and Riordan, N. H. (2014). Osteodifferentiated mesenchymal stem cells from bone marrow and hyaluronic acid gel. Stem Cells Transl. Med. 3, 571–579. doi: 10.1038/scitox.2014.383
Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M., and Lagneaux, L. (2016). Mesenchymal stem cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy 18, 160–171. doi: 10.1016/j.jcyt.2015.10.011
Najar, M., Raicevic, G., Fayyad-Kazan, H., Bron, D., Toungouz, M., et al. (2013). Impact of different mesenchymal stem cell types on T-cell activation, proliferation and migration. Int. Immunopharmacol. 15, 693–702. doi: 10.1016/j.intimp.2013.02.020
Nannarco-Lewi, R., Mafi, P., Mafi, R., and Khan, W. (2017). A systemic review of adult mesenchymal stem cell sources and their multilineage differentiation potential relevant to musculoskeletal tissue repair and regeneration. Curr. Stem Cell Res. Ther. 12, 601–610. doi: 10.2174/1574889X126661706124030
Napiò, C., William-Ignarro, S., Byrns, R., Balestrieri, M. L., Crimi, E., Farzati, B., et al. (2008). Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nat. Clin. Pract. Cardiovasc. Med. 5, 571–579. doi: 10.1038/ncpcardio1214
Nasef, A., Mathieu, N., Chapel, A., Frick, J., François, S., Mazurier, C., et al. (2007). Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84, 231–237. doi: 10.1097/tp.0b013e3180b97008
Neri, S. (2019). Genetic stability of mesenchymal stem cells for regenerative medicine applications: a fundamental biosafety aspect. Int. J. Mol. Sci. 20:E2406. doi: 10.3390/ijms20120406
Nürnberger, S., Lindner, C., Maier, J., Strohmeier, K., Wurzer, C., Sleizak, P., et al. (2019). Adipose-tissue-derived therapeutic cells in their natural environment as an autologous cell therapy strategy: the microtissue-stromal vascular fraction. Eur. Cell Mater. 37, 113–133. doi: 10.22203/cem.v037a08
Ock, S. A., Lee, Y. M., Park, J. S., Shivakumar, S. B., Moon, S. W., Sung, N. J., et al. (2016). Evaluation of phenotypic, functional and molecular characteristics of porcine mesenchymal stromal/stem cells depending on donor age, gender and tissue source. J. Vet. Med. Sci. 78, 987–995. doi: 10.1292/jvms.15-0596
Oh, S. H., Choi, C., Chang, D. J., Shin, D. A., Lee, N., Jeon, I., et al. (2015). Early neuroprotective effect with lack of long-term cell replacement effect on experimental stroke after intra-arterial transplantation of adipose-derived mesenchymal stem cells. Cytotherapy 17, 1090–1103. doi: 10.1016/j.jcyt.2015.04.007
Oháte, B., Viláhur, G., Camino-López, S., Diez-Caballero, A., Ballesta-López, C., Ybarra, J., et al. (2013). Stem cells isolated from adipose tissue of obese patients show changes in their transcriptomic profile that indicate loss in stemness and increased commitment to an adipocyte-like phenotype. BMC Genomics 14:625. doi: 10.1186/1471-2164-14-625
Oháte, B., Viláhur, G., Ferrer-Lorente, R., Ybarra, J., Diez-Caballero, A., Ballesta-López, C., et al. (2012). The subcutaneous adipose tissue reservoir of functionally active stem cells is reduced in obese patients. FASEB J. 26, 4327–4336. doi: 10.1096/fj.12-207217
Onesti, M. G., Carella, S., Ceccarelli, S., Marchese, C., and Scuderi, N. (2016). The use of human adipose-derived stem cells in the treatment of physiological and pathological vulvar dysstrophies. Stem Cells Int. 2016:2561461. doi: 10.1155/2016/2561461
Panés, J., García-Olmo, D., Van Assche, G., Colombel, J. F., Reinisch, W., Baumgart, D. C., et al. (2016). Expanded allogeneic adipose-derived mesenchymal stem cells (Ca601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388, 1281–1290. doi: 10.1016/S0140-6736(16)31203-x
Park, I. S., Chung, P. S., and Ahn, J. C. (2017). Adipose-derived stem cell spheroid treated with low-level light irradiation accelerates spontaneous angiogenesis in mouse model of hindlimb ischemia. Cytotherapy 19, 1070–1078. doi: 10.1016/j.jcyt.2017.06.005
Park, M. J., Kwok, S. K., Lee, S. H., Kim, E. K., Park, S. H., and Cho, M. L. (2015). Adipose tissue-derived mesenchymal stem cells induce expansion of interleukin-10-producing regulatory T cells and ameliorate autoimmunity in a murine model of systemic lupus erythematosus. Cell Transplant. 24, 2367–2377. doi: 10.3727/096368914X685645

Patrikosi, M., Sivula, J., Huhata, H., Helminen, M., Salo, F., Mannström, B., et al. (2014). Different culture conditions modulate the immunomodulatory properties of adipose stem cells. Stem Cells Transl. Med. 3, 1220–1230. doi: 10.5966/sctm.2013-0201

Payne, N. L., Dantanarayana, A., Sun, G., Moussa, L., Caine, S., McDonald, C., et al. (2012). Early intervention with gene-modified mesenchymal stem cells overexpressing interleukin-4 enhances anti-inflammatory responses and functional recovery in experimental autoimmune demyelination. Cell Adhes. Migr. 6, 179–189. doi: 10.4161/cam.20341

Peng, Y., Chen, X., Liu, Q., Zhang, X., Huang, K., Liu, L., et al. (2015). Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia 29, 636–646. doi: 10.1038/leeu.2014.225

Pers, Y.-M., Rackwitz, L., Ferreira, R., Pullig, O., Delfour, C., Barry, F., et al. (2016). Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase i dose-escalation trial. Stem Cells Transl. Med. 5, 847–856. doi: 10.5966/sctm.2015-0245

Planat-Bénard, V., Menard, C., André, M., Puceat, M., Perez, A., Garcia-Verdugo, J. M., et al. (2004). Spontaneous cardiomyocyte differentiation from adipose tissue stroma cells. Circ. Res. 94, 223–229. doi: 10.1161/01.res.0000109792.43271.47

Polichà, A., Zhang, P., Chang, L., Lamb, K., Tulenko, T., and DiMuzio, P. (2014). Endothelial differentiation of diabetic adipose-derived stem cells. J. Surg. Res. 192, 656–663. doi: 10.1016/j.jss.2014.06.041

Poloni, A., Maurizi, G., Ciarlantini, M., Medici, M., Mattiucci, D., Mancini, S., et al. (2015). Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation. Cytotherapy 17, 1292–1301. doi: 10.1177/1463923615055836

Puissant, B., Barreau, C., Bourin, P., Clavel, C., Corre, J., Bousquet, C., et al. (2005). Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 129, 118–129. doi: 10.1111/j.1365-2141.2005.05409.x

Qi, H., Chen, G., Huang, Y., Si, Z., and Li, J. (2015). Foxp3-modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats. J. Transl. Med. 13:274. doi: 10.1186/s12967-015-0638-2

Regmi, S., Pathak, S., Thanh, T. P., Nguyen, T. T., Sung, J. H., Yook, S., et al. (2019). Intraperitoneally delivered stem cell spheroids localize in the liver and protect hepatocytes against GaIN/LPS-induced fulminant hepatic toxicity. Stem Cell Res. Ther. 10:230. doi: 10.1186/s13287-019-1337-3

Ribeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., et al. (2013). Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res. Ther. 4:125. doi: 10.1186/s13287-013-0063-8

Russell, K. A., Chow, N. H. C., Dukoff, D., Gibson, T. W. G., La Marre, J., Betts, Sabia, C., Picascia, A., Grimaldi, V., Amarelli, C., Maiello, C., and Napoli, C. Ryan, J. M., Barry, F., Murphy, J. M., and Mahon, B. P. (2007). Interferon-Ribeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., et al. (2013). Regmi, S., Pathak, S., Thanh, T. P., Nguyen, T. T., Sung, J. H., Yook, S., et al. (2019). Intraperitoneally delivered stem cell spheroids localize in the liver and protect hepatocytes against GaIN/LPS-induced fulminant hepatic toxicity. Stem Cell Res. Ther. 10:230. doi: 10.1186/s13287-019-1337-3

Semon, J. A., Maness, C., Zhang, X., Shanky, S. A., Beutler, M. M., Shaf, F. S., et al. (2014). Comparison of human adult stem cells from adipose tissue and bone marrow in the treatment of experimental autoimmune encephalomyelitis. Stem Cell Res. Ther. 5:2. doi: 10.1186/s13287-013-0063-8
stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. *Stem Cells Int.* 2010, 582382. doi: 10.4061/2010/582382

Varghese, J., Griffin, M., Mosahabi, A., and Butler, P. (2017). Systematic review of patient factors affecting adipose stem cell viability and function: implications for regenerative therapy. *Stem Cell Res. Ther.* 8:45. doi: 10.1186/s13287-017-0483-8

Veldier, M., Simoncini, S., Abellan, M., Francois, P., Eap, S., Lagrange, A., et al. (2019). Adipose-derived stem cells from systemic sclerosis patients maintain pro-angiogenic and anti-fibrotic paracrine effects in vitro. *J. Clin. Med.* 8:E1979. doi: 10.3390/jcm8111979

Voog, J., and Jones, D. L. (2010). Stem cells and the niche: a dynamic duo. *Cell Stem Cell* 6, 103–115. doi: 10.1016/j.stem.2010.01.011

Waldner, M., Zhang, W., James, I. B., Allbright, K., Havis, K., Havis, E., Bliley, J. M., et al. (2018). Characteristics and immunomodulating functions of adipose-derived and bone marrow-derived mesenchymal stem cells across defined human leukocyte antigen barriers. *Front. Immunol.* 9:1642. doi: 10.3389/fimmu.2018.01642

Wang, Y. H., Huang, X. H., Yang, Y. M., He, Y., Dong, X. H., Yang, H. X., et al. (2019). Mysm1 epigenetically regulates the immunomodulatory function of adipose-derived stem cells in part by targeting miR-150. *J. Cell. Mol. Med.* 23, 3737–3746. doi: 10.1111/jcmm.14281

Waterman, R. S., Tomchuck, S. L., Henkle, S. L., and Betancourt, A. M. (2010). A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. *PLoS One* 5:e10088. doi: 10.1371/journal.pone.0010088

Xu, Y., Shi, T., Xu, A., and Zhang, L. (2016). 3D spheroid culture enhances survival and therapeutic capacities of MSCs injected into ischemic kidney. *J. Cell. Mol. Med.* 20, 1203–1213. doi: 10.1111/jcmm.12651

Yan, Y., Ma, T., Gong, K., Ao, Q., Zhang, X., and Gong, Y. (2014). Adipose-derived mesenchymal stem cell transplantation promotes adult neurogenesis in the brains of Alzheimer’s disease mice. *Neural Regen. Res.* 9, 798–805.

Yahez, R., Lamana, M. L., García-Castro, J., Colmenero, I., Ramirez, M., and Bueren, J. A. (2006). Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. *Stem Cells* 24, 2582–2591. doi: 10.1634/stemcells.2006-0228

Yang, D., Wang, W., Li, L., Peng, Y., Chen, P., Huang, H., et al. (2013). The relative contribution of paracrine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair. *PLoS One* 8:e59020. doi: 10.1371/journal.pone.0059020

Yang, H. M., Sung, J. H., Choi, Y. S., Lee, H. J., Roh, C. R., Kim, J., et al. (2012). Enhancement of the immunosuppressive effect of human adipose tissue-derived mesenchymal stromal cells through HLA-G1 expression. *Cytotherapy* 14, 70–79. doi: 10.3109/14653249.2011.613926

Yokota, N., Yamakawa, M., Shirata, T., Kimura, T., and Kaneshima, H. (2017). Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee. *Regen. Ther.* 6, 108–112. doi: 10.1016/j.reth.2017.04.002

Yousefi, F., Ebtekar, M., Soleymani, M., Soudi, S., and Hashemi, S. M. (2013). Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). *Int. Immunopharmacol.* 17, 608–616. doi: 10.1016/j.intimp.2013.07.016

Yu, B., Yu, D., Cao, L., Zhao, X., Long, T., Liu, G., et al. (2011). Simulated microgravity using a rotating cell culture system promotes chondrogenesis of human adipose-derived mesenchymal stem cells via the p38 MAPK pathway. *Biochem. Biophys. Res. Commun.* 414, 412–418. doi: 10.1016/j.bbrc.2011.09.103

Zhai, N., Li, H., Yan, Y., Jiang, R., and He, X. (2017). Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4+ T cell function. *Cell. Immunol.* 312, 61–66. doi: 10.1016/j.cellimm.2016.12.001

Zhao, S., Wehner, R., Bornhäuser, M., Wassmuth, R., Bachmann, M., and Schmitz, M. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. *Stem Cells Dev.* 19, 607–614. doi: 10.1089/scd.2009.0345

Zhou, K., Guo, S., Tong, S., Sun, Q., Li, F., Zhang, X., et al. (2018). Immunosuppression of human adipose-derived stem cells on T cell subsets via the reduction of NF-kappaB activation mediated by PD-L1/PD-1 and Gal-9/TIM-3 Pathways. *Stem Cells Dev.* 27, 1191–1202. doi: 10.1089/scd.2018.0033

Zuk, P. A., Zhu, M., Ashjian, P., De Ugarte, D. A., Huang, J. I., Mizuno, H., et al. (2002). Human adipose tissue is a source of multipotent stem cells. *Mol. Biol. Cell* 13, 4279–4295.

Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., et al. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng.* 7, 211–228. doi: 10.1089/107632701300062859

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Ceccarelli, Pontecorvi, Anastasissadou, Napoli and Marchese. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*